Table 4.
Adverse events reported by more than one participant: number (percentage) of participants reporting
| Event | Borage oil (n=85) | Placebo (n=55) |
|---|---|---|
| Upper respiratory tract infection | 22 (26) | 21 (38) |
| Diarrhoea | 6 (7) | 6 (11) |
| Nausea, vomiting, or both | 3 (4) | 5 (9) |
| Abdominal pain | 5 (6) | 2 (4) |
| Episodes of asthma | 1 (1) | 4 (7) |
| Episodes of allergic rhinitis | 1 (1) | 1 (2) |
| Episodes of urticaria | 2 (2) | 1 (2) |
| New rash | 0 | 2 (4) |
| Musculoskeletal pains | 3 (4) | 3 (6) |
| Skin sepsis | 6 (7) | 7 (13) |
| Glandular fever | 2 (2) | 0 |
| Headache | 1 (1) | 4 (7) |